Results 91 to 100 of about 16,960 (297)

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single‐centre study

British Journal of Clinical Pharmacology, EarlyView.
Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga, Stefano Agliardi, Riccardo Giossi, Alice Schianchi, Alessandra Romandini, Thomas Virdis, Silvia Nerini Molteni, Maria Luisa De Angelis, Stefania Paccagnini, Cecilia Gechtman, Alice Proto, Marco Fossati, Silvia Oliveri, Giulia Angela Pattarino, Elena Altieri, Agnese Graziosi, Arianna Pani, Romano Danesi, Stefano Martinelli, Costantino De Giacomo, Francesco Scaglione   +20 more
wiley   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source

Spread of Tst–Positive Staphylococcus aureus Strains Belonging to ST30 Clone among Patients and Healthcare Workers in Two Intensive Care Units

Toxins, 2017
Staphylococcus aureus is a major cause of infections. Toxic shock syndrome toxin (TSST-1) and Panton–Valentine leukocidin (PVL) are associated with severe clinical syndromes. S. aureus colonizing isolates recovered from healthcare workers and patients in
Matthaios Papadimitriou-Olivgeris, Eleanna Drougka, Fotini Fligou, Vasiliki Dodou, Fevronia Kolonitsiou, Kriton S. Filos, Evangelos D. Anastassiou, Efthimia Petinaki, Markos Marangos, Iris Spiliopoulou   +9 more
doaj   +1 more source

Analysis of superantigenic toxin Vβ T-cell signatures produced during cases of staphylococcal toxic shock syndrome and septic shock

, 2008
Most clinical isolates of Staphylococcus aureus harbour genes encoding superantigenic toxins that bind the Vβ domain of T-cells, but little information is available concerning superantigenic toxin production during staphylococcal toxic shock syndrome ...
Perpoint, T., D. Peyramond, F. Vandenesch, Lina, G., Monneret, G., Peyramond, D., G. Lina, Etienne, J., C. Chidiac, Mohammedi, I., Vandenesch, F., Ferry, T., T. Ferry, I. Mohammedi, D. Thomas, Chidiac, C., G. Monneret, T. Perpoint, Thomas, D., J. Etienne   +19 more
core   +1 more source

Table_1_Toxin exposure and HLA alleles determine serum antibody binding to toxic shock syndrome toxin 1 (TSST-1) of Staphylococcus aureus.pdf

, 2023
Life-threatening toxic shock syndrome is often caused by the superantigen toxic shock syndrome toxin-1 (TSST-1) produced by Staphylococcus aureus. A well-known risk factor is the lack of neutralizing antibodies.
Marcus Dörr (112711), Stephan Michalik (1997962), Matthias Nauck (112743), Nele Friedrich (329201), Cedric Mahncke (16927644), Stefanie Samietz (300852), Tanja C. Meyer (7054115), Barbara M. Bröker (8786336), Georg Homuth (110202), Stefan Weiss (1474864), Stephan B. Felix (112722), Silva Holtfreter (252366), Clemens Cammann (3479999), Hans J. Grabe (10136830), Christian Kohler (655546), Frieder Schmiedeke (16927641), Uwe Völker (112748), Henry Völzke (64286)   +17 more
core   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Table_2_Toxin exposure and HLA alleles determine serum antibody binding to toxic shock syndrome toxin 1 (TSST-1) of Staphylococcus aureus.pdf

, 2023
Life-threatening toxic shock syndrome is often caused by the superantigen toxic shock syndrome toxin-1 (TSST-1) produced by Staphylococcus aureus. A well-known risk factor is the lack of neutralizing antibodies.
Marcus Dörr (112711), Stephan Michalik (1997962), Matthias Nauck (112743), Nele Friedrich (329201), Cedric Mahncke (16927644), Stefanie Samietz (300852), Tanja C. Meyer (7054115), Barbara M. Bröker (8786336), Georg Homuth (110202), Stefan Weiss (1474864), Stephan B. Felix (112722), Silva Holtfreter (252366), Clemens Cammann (3479999), Hans J. Grabe (10136830), Christian Kohler (655546), Frieder Schmiedeke (16927641), Uwe Völker (112748), Henry Völzke (64286)   +17 more
core   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

BMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang   +6 more
wiley   +1 more source

Sloughing skin in intravenous drug user

IDCases, 2018
A 32 year old female, an active intravenous drug user, was admitted for fever, myalgias and an erythematous macular rash on her distal extremities. She quickly decompensated and developed septic shock.
Shrein Saini, Robert A. Duncan
doaj   +1 more source

Expression of cholera toxin B subunit in Saccharomyces cerevisiae [PDF]

Cholera toxin, secreted by Vibrio cholerae, consists of A and B subunits. Cholera toxin B subunit (CTB) is used in many scientific research. It has already been expressed in several bacterial and plant systems.
ارزنلو, محسن, آهنگرزاده رضایی, محمد, زواران حسینی, احمد, توچیکوبو, کونیو, شاهرخی, نادر, یاسودا, یوکو, رضایی, عباس   +6 more
core